Satoshi Yoshida

Learn More
AIMS/INTRODUCTION In the present dose-response study, we evaluated the efficacy and safety of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose cotransporter 2, in(More)